Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
14 August 2020 | Story Amanda Tongha | Photo NSFAS
Applications for the National Student Financial Aid Scheme (NSFAS) 2021 are now open.  

The NSFAS application cycle will run for a period of four months starting from 3 August to 30 November 2020. 

NSFAS applications are open to students from poor and working-class backgrounds who wish to further their studies at any public Technical and Vocational Education and Training (TVET) college or university. To qualify for NSFAS funding, the applicant must be a South African citizen; come from a family with a combined annual household income of not more than R350 000; for students with a disability, a combined annual household income of not more than R600 000. 

Applications for 2021 funding will be completed online via the myNSFAS portal as per previous years. 

New applicants need a copy of their ID or birth certificate to register and create a myNSFAS account or profile on the myNSFAS portal. Applicants with existing accounts must log on to their accounts to complete an application. Applicants are not allowed to create more than one profile on the portal. The applicant will be required to give consent to NSFAS to verify their personal information with third parties and will not be able to create a profile without giving this consent. This feature allows NSFAS to conduct a three-step verification process with the Department of Home Affairs (DHA), where an ID number will be linked to the name and surname of the applicant and the parents' details. 

In response to the status quo due to the COVID-19 pandemic, applicants will not be required to submit or upload the consent form; however, they will have to grant consent electronically during the application process, along with accepting the terms and conditions for funding. 

Applicants will, however, still be required to submit their supporting documents, comprising a copy of own ID; parents’/guardian's proof of income; copies of parents’/guardian's ID; and/or Annexure A for applicants with disabilities. 

Qualifying students are urged to make use of this opportunity and apply for funding in time. 

 
 

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept